Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.

Kim A. Reiss,Rosemarie Mick,Mark H. OHara,Ursina R. Teitelbaum,Thomas B. Karasic,Charles Schneider,Stacy Cowden,Traci Southwell,Janae Romeo,Natallia Izgur,Zain M. Hannan,Rashmi Tondon,Katherine L. Nathanson,Robert H. Vonderheide,Max M. Wattenberg,Gregory L. Beatty,Susan M. Domchek

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.

2021

Kim A. Reiss
Rosemarie Mick
Mark H. OHara
Ursina R. Teitelbaum
Thomas B. Karasic
Charles Schneider
Stacy Cowden
Traci Southwell
Janae Romeo
Natallia Izgur
Zain M. Hannan
Rashmi Tondon
Katherine L. Nathanson
Robert H. Vonderheide
Max M. Wattenberg
Gregory L. Beatty
Susan M. Domchek

PURPOSEOlaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogen...

Keywords:

Polymerase
Germline
Cancer research
Maintenance therapy
PALB2
Somatic cell
Poly ADP ribose polymerase
Pancreatic cancer
Rucaparib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations